Lupin Introduces Bumetanide Injection, USP in United States
Overview
Global pharma major Lupin Limited (Lupin) announced the launch of United Food and Drug Administration (FDA) approved bumetanide injection USP, 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multiple-dose vials in the United States.
Bumetanide Injection: Indication
Bumetanide injection USP, is a generic equivalent of Bumex injection, 0.25 mg/mL of Validus Pharmaceuticals, LLC., indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.
Bumetanide Injection: Annual Sale
Bumetanide injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US (IQVIA MAT September 2024).
About the Company: Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets.
Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!